Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Countries at the United Nations COP29 climate summit struck a deal on the basic rules to launch an international carbon trading market.
Three major event films — Wicked, Gladiator II, and Moana 2 — set to dominate multiplex screens this Thanksgiving week.
Novartis is banking on the startup’s promising treatment candidates for neuromuscular diseases, many of which are genetic in nature.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
The House of Mouse hopes to double the size of its leisure fleet by 2031 in an “unprecedented period of growth.”
Military tech startups are seeing a big boost in their valuations of late, spurred in part by former President Trump’s re-election.
Walmart announced that it’s raising its outlook for the year, thanks in part to a rocking start to the holiday shopping season.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Budget-friendly Spirit Airlines hasn’t reported an annual profit since 2019, and has lost some $2.2 billion since 2020.
The Trump White House may usher in a big loosening of the rules around cars that can operate without human drivers.
The longtime broadcast partner may soon be losing out on live games, but Warner Bros. Discovery won’t be completely sidelined by the NBA.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.